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Introduction
Gastrointestinal stromal tumors (GISTs) are the most 
common mesenchymal tumors of the intestinal track and 
are thought to originate from the interstitial cells of Cajal 
(ICCs). There are approximately 5,000 new cases diagnosed 
each year and an ever-growing prevalence (1). While GISTs 
can arise anywhere from esophagus to rectum, the majority 
originate in the stomach (1,2). Previously, GISTs were 
very difficult to treat as they are refractory to traditional 
cytotoxic chemotherapy (3). In the past 10 years, the rapid 
evolution of this field has led to the continued need to 
collaborate between academic and private practitioners to 
optimize individualized therapy.
Management of GIST patients is divided into resectable 
disease that may need neoadjuvant/adjuvant therapy and 
metastatic disease that requires palliative tyrosine kinase 
inhibition. Our understanding of which therapies are most 
efficacious with each mutation has also established GIST 
as a model for targeted therapies in solid tumors. Clear 
guidelines have been developed regarding staging, prognosis 
and treatment (4). In addition, detailed provides correlations 
between current point mutations and response are available 
(https://www.mycancergenome.org/content/disease/gist/
correlates). A deeper understanding of the molecular 
pathogenesis and driving role of the proto-oncogenes 
KIT and PDGRFα has transformed the treatment of both 
localized and metastatic disease. Herein we will review how 
therapeutic tyrosine kinase inhibitor (TKI) management is 
affected by mutational status. 
Diagnosis and standard management
The diagnosis of GIST is based on a combination of 
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imaging findings and pathology (4). Asymptomatic lesions 
are usually identified by upper endoscopy or as an incidental 
finding on other imaging modalities (5). Symptomatic 
GISTs are either found on imaging workup for the 
presenting symptom or found because of an emergent 
surgery in extreme cases (6). Obtaining tissue by biopsy or 
surgery then results in a definitive diagnosis. Historically, 
GISTs were considered to be of smooth muscle origin and 
were originally named gastric leiomyosarcomas. However, in 
the 1980’s electron microscopy and immunohistochemistry 
were used by Mazur and colleagues to demonstrate 
that these tumors differ from leiomyosarcomas, and as 
such they proposed the term GISTs (7). In the 1990’s 
researchers identified similarities between GISTs and ICCs, 
a population of cells in the gut. These cells were found 
to express cKIT/CD117 (8). Shortly thereafter, Hirota 
and colleagues discovered that GISTs express CD117 as 
well (2). Today, it is hypothesized that ICCs are the cell of 
origin for GIST and it is clear that 95% of GISTs express 
cKIT/CD117 by immunohistochemistry forming the basis 
for diagnosis of this tumor. Later in the 1990’s DOG-1 
was identified as another immunohistochemical marker of 
GIST as it is expressed in approximately 98% of GIST (9). 
The combination of cKIT/CD117 and DOG-1 staining is 
virtually diagnostic of this tumor.
The first report of gain-of-function mutations in 
cKIT/CD117 in GIST paved the way for the molecular 
characterization of these tumors. Today, we know that 
75–80% of GISTs will harbor a mutation in cKIT. It 
was subsequently discovered that 10% of GISTs would 
have a mutation in PDGFRα, leaving 10–15% of GISTs 
that lack a mutation in either of these genes. This group 
has historically been termed wild-type (WT) GIST, but 
this grouping is likely too broad and non-specific, as it 
encompasses a diverse molecular population (10). The 
molecular subtype of GIST (mutational characterization) 
is important for prognosis and treatment planning (11,12). 
Below we detail the clinical significance of known molecular 
alterations, supporting the need for sequencing all GISTs 
for mutations in KIT and PDGFRα at the time of diagnosis. 
Adjuvant therapy data for imatinib
A role for adjuvant imatinib was first demonstrated in the 
ACOSOG Z9001 trial in which patients with a completely 
excised GIST measuring at least 3 centimeters were 
randomized to 1 year of imatinib versus placebo (13). 
While relapse free survival was improved at one year in 
the imatinib arm (98% vs. 83%: HR =0.35), the rate of 
recurrence increased in the imatinib arm approximately 
6 months after completion of adjuvant therapy. Given 
these findings, a longer duration of therapy was examined. 
The Swedish study, SSG XVIII, compared 1 vs. 3 years of 
adjuvant imatinib in high risk cKIT positive GISTs. In this 
study, high-risk patients as defined as those with tumors 
greater than 10 cm in size, mitotic count greater than 
10 mitoses/50 high power fields, 5 cm in size with a mitotic 
count of greater than 5 mitoses/50 high power fields, or 
tumor rupture at time of surgery were enrolled. In this high 
risk group, those patients on 3 years of adjuvant imatinib 
demonstrated improved relapse free survival at 5 years 
(65.6% vs. 47.9%), as well as an improved overall survival 
at 5 years (92% vs. 81.7%) (14,15). These findings have 
solidified the use of 3 years of adjuvant imatinib as a current 
standard of care for high risk resected GISTs.
TKI pathway in the metastatic setting
A TKI treatment paradigm was initially developed and 
has been used irrespective of point mutational status. 
This pathway is now evolving with current mutational 
understating. Imatinib given at 400 mg per day was granted 
accelerated FDA approval for advanced or metastatic 
GIST in 2002 (16). Dose escalation from 400 mg daily to 
800mg (400 mg twice a day) at the time of progression has 
been shown to be effective at achieving prolonged disease 
stability (17,18). Sunitinib on 6 week cycles of 4 weeks 
of 50mg daily followed by 2 weeks off was subsequently 
approved in 2006 for imatinib-refractory patients (19). 
Finally, regorafenib was approved in 2013 on the basis of 
improved progression free survival compared to placebo 
in patients refractory to or intolerant of sunitinib. The 
approved dose for regorafenib is 160 mg daily on a 3 weeks 
on 1 week off schedule (20).
cKIT mutations
Over 95% of GISTs express  cKIT, a  cel l  surface 
transmembrane receptor tyrosine kinase. It has been nearly 
twenty years since Hirota’s group first identified gain of 
function mutations in KIT as a driver in the oncogenesis 
of GISTs (2). The most common mutations arise in the 
juxtamembrane domain encoded by exon 11, followed 
by mutations in the extracellular domain often due to 
duplications in exon 9, mutations in exons 13 and 14 which 
affect the ATP-binding pocket, and mutations in exon 
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17 which are located in the true kinase domain (Figure 1).
Exon 11
KIT mutations in exon 11 are the most common mutation 
in GISTs and are identified in approximately 70% of 
cases. As a group, exon 11 mutations portend a high risk 
of relapse after surgical resection. While the ACOSOG 
Z9001 trial demonstrated improved relapse free survival 
(HR =0.35) in patients with resected GIST when treated 
with a year of adjuvant imatinib compared to placebo (13), 
subsequent molecular profi l ing of tumor samples 
demonstrated significant heterogeneity in the benefit based 
on the underlying mutation. Fortunately, GIST tumors 
with exon 11 mutations seem to drive this benefit with a 
two-year relapse free survival of 91% in the imatinib arm 
compared to 65% in the placebo arm (P<0.0001) (21). 
Subsequently, the SSG XVIII trial evaluated the potential 
benefit of extending adjuvant therapy from 1 to 3 years (14). 
Exon 11 mutations demonstrate a clear benefit to extended 
adjuvant therapy (HR =0.31; 95% CI: 0.22–0.56). Based on 
these results, standard of care is to offer at least three years 
of adjuvant imatinib to high risk resected GISTs harboring 
an exon 11 mutation. 
In the metastatic setting, exon 11 mutations confer an 
exquisite sensitivity to imatinib. Based on phase II trial 
data, partial response rates exceed 80% in patients with 
exon 11 mutations treated with 400 mg daily of imatinib, a 
significantly higher response rate than had been seen in any 
other subgroup of GIST patients (22). In addition, these 
responses are prolonged with a median event free survival of 
just under 2 years (687 days) (22). Subsequent phase III trials 
have failed to show any benefit to initiating higher doses of 
imatinib in the upfront setting for exon 11 mutations (11). In 
the second line setting, the benefit of sunitinib is much more 
modest, providing, on average, a PFS of 5.1 months (23). 
The benefit of third line regorafenib compared to placebo 
was likewise modest, but real, in this population (HR =0.212; 
95% CI: 0.098–0.458) (20).
Exon 9
Nucleotide duplications in exon 9 represent the second 
most common mutation in GISTs and account for 10–15% 
of newly diagnosed cases (22). These mutations are seen 
much more commonly in GISTs arising from the small 
intestine and are relatively uncommon in those which arise 
in the stomach or large intestine. Compared to the more 
common exon 11 mutations, GISTs with exon 9 mutations 
tend to have better relapse free survival after curative 
resection. However, the exon 9 mutated GISTs benefit less 
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Figure 1 Cartoon representing the distribution of point mutations in cKIT and PDGFRa by exon. While most mutations occur in exon 11 
of cKIT (70%), others commonly occur in cKIT at exons 9, 13, 14 and 17 and in PDGFRa at exons 12 and 18.
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Analysis of the ACOSOG Z9001 data failed to demonstrate 
a statistically significant benefit in relapse free survival with 
1 year of adjuvant imatinib compared to placebo (21). While 
this could be attributed to small sample size, the SSG XVIII 
trial likewise failed to show a significant benefit of 3 years 
of adjuvant imatinib over 1 year of treatment in the exon 
9 mutated population. Further, there is no data for higher 
doses of imatinib in the adjuvant setting. 
In the metastatic or unresectable setting, one can 
anticipate intermediate responsiveness to imatinib therapy. 
In phase II studies, partial responses were seen in 47.8% 
of patients treated with 400mg of imatinib (22). Two 
subsequent phase III studies have demonstrated that carriers 
of the exon 9 mutations have a better response rate to a 
higher dose of imatinib (800 mg daily compared to 400 mg). 
The progression free survival (PFS) data, however, are 
somewhat conflicting. In an EORTC trial, patients with 
exon 9 mutations had a marked improvement in PFS 
with a 61% relative risk reduction (P=0.0013) in disease 
progression, leading the authors to conclude that patients 
with metastatic GIST harboring an exon 9 mutation should 
be treated with 800mg of imatinib upfront (12). However, 
while the North American trial demonstrated a numerical 
improvement in PFS with 800mg daily (18.0 vs. 9.4 months 
for 800 vs. 400 mg), this finding was not statistically 
significant (11). Neither trial demonstrated an overall 
survival benefit, but crossover from 400 to 800 mg at the 
time of progression was allowed in each study, potentially 
confounding this finding. 
Despite the somewhat disappointing benefits of front line 
imatinib, the clinical benefit of second line sunitinib can be 
quite impressive in the treatment of metastatic GIST with an 
exon 9 mutation. Heinrich and colleagues reported PFS of 
19 months and overall survival over 2 years in this setting (24). 
Regorafenib as a third line option has demonstrated some 
improvement in exon 9 mutated GISTs with benefits similar 
to that seen in exon 11 mutated tumors (20).
Exons 13/14
Primary mutations in exons 13 and 14 of KIT are 
uncommon and have been identified in approximately 1–2% 
of newly diagnosed GISTs. Of the 397 KIT positive GISTs 
in the CALGB 150105 trial, 5 were found to have primary 
exon 13 mutations and none with exon 14. Clinical benefit 
to imatinib was demonstrated in 3 of these 5 patients (11).
These mutations do appear more frequently and are 
of greater clinical significance in the setting of secondary 
imatinib resistance (23). Mutations in exons 13 and 
14 affect the ATP binding site, which is also the binding site 
for imatinib and other TKIs. Among the most common of 
these mutations are the V654A mutation in exon 13 and the 
T670I mutation seen in exon 14 (24). Sunitinib effectively 
inhibits these mutant kinases (25). which has translated 
into a clinical benefit, as sunitinib has demonstrated a 
significantly longer PFS for patients harboring secondary 
mutations in exons 13 and 14 compared to other secondary 
mutations, such as those in exon 17 (PFS 7.8 vs. 2.3 months; 
P=0.0157) (23). There is a paucity of data on the benefits of 
regorafenib in the low incidence mutations, and the clinical 
utility is unclear in this patient population.
Exon 17
Primary mutations in exon 17 are rare, accounting for 
approximately 1% of newly diagnosed GISTs and classically 
involve codons 816, 820, or 823 (26). These exon 17 mutations 
arise more commonly in tumors in the small intestine 
compared to those in the stomach or other sections of 
the GI tract (27). Treatment of these tumors is guided by 
small numbers of patients included in clinical trials. For 
example, 3 of 4 patients with unresectable disease with 
primary exon 17 mutations demonstrated clinical benefit 
(3 partial responses, 1 stable disease) to treatment with 
imatinib (12,22,). However, as secondary mutations, exon 
17 mutations are often responsible for acquired imatinib 
resistance, potentially accounting for as many as 50% of 
the acquired resistance cases (28). The D816V and N822V 
substitutions, for example, have been associated with 
imatinib resistance and also confer resistance to second line 
sunitinib (23). Ponatinib has demonstrated strong activity 
against exon 17 mutations in vitro, and early studies suggest 
some benefit in heavily pre-treated GIST patients (28). 
There is new potent inhibitor of these resistance mutations, 
BLU-285, which is in early phases of development and has 
demonstrated activity in cellular assays. This suggests that 
a new agent that may work in imatinib driven resistance 
mutations (29). The development of BLU-285 has the 
potential to be transformative to the field of GIST therapy.
PDGFRα mutations
Mutations in PDGFRα are much less frequent than KIT 
mutations, and as a group, are found only in 5–10% of 
newly diagnosed GISTs. Gain-of-function mutations in 
PDGFRα, however, drive the same pathways seen in KIT 
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mutant GISTs, namely MAP kinase and PI3K/AKT. Gain-
of-function mutations have been identified in exon 18, the 
tyrosine kinase domain, as well exon 12, the juxtamembrane 
domain. 
Exon 18/ D842V
Among the PDGFRα variants, mutations in exon 18 are the 
most common. While over a dozen specific mutations in 
exon 18 have been identified, the D842V substitution is the 
most frequent and accounts for over 60% of the PDGFRα 
mutations (30). In vitro studies have demonstrated that the 
D842V mutation confers resistance to imatinib by blocking 
its ability to bind to the ATP-binding site. None of the 
three patients with the D842V mutation in Heinrich’s 
analysis achieved clinical benefit from palliative imatinib 
therapy. In spite of limited clinical evidence, it is felt that 
the D842V mutation also confers resistance to sunitinib 
and regorafenib (22,23). However, ongoing research has 
demonstrated areas of promise. Ponatinib has potential 
activity against D842V (31). Additionally, Crenolanib is an 
oral TKI, which targets PDGFRAα/β and has demonstrated 
activity against D842V mutant GIST cell lines (as well as 
other imatinib resistant PDGFRα mutants) (32). Phase 
I-II trials have been completed, and crenolanib is moving 
forward in phase III trials in both Europe and the United 
States. In addition, BLU-285 also has demonstrated activity 
in D842V models and is currently in phase I testing (29).
Within non D842V exon 18 mutations, imatinib has 
shown significant activity in vitro. While too few of these 
patients have been included in clinical trials to draw a 
conclusion regarding the benefit of imatinib in vivo, it is 
felt that treatment with available TKIs is warranted. In the 
adjuvant setting, there was no clear benefit to three years of 
imatinib (14). However, this could have been a reflection of 
small sample size rather than lack of effect. There is limited 
data for the utility of imatinib in the palliative setting. 
Within a registry of 823 Korean patients with GISTs, 
35 patients were found to have mutations in PDGFRα. 
Of these, only 4 had non D842V exon 18 mutations. All 
4 patients achieved a partial response to first line imatinib 
and only one patient of these 4 went on to second line 
therapy with sunitinib. Of note, that patient did at least 
achieve stable disease (33).
Exon 12
Mutations in exon 12 are rare, but do represent the third 
most common mutation in PDGFRα. Patients with this 
mutation seem to have similar benefits to first line imatinib 
as the non-D842V exon 18 mutations. In a group of 
8 patients with exon 12 mutations, 7 of 8 proved to have 
clinical benefit to imatinib (1 complete response, 3 partial 
responses, and 3 with stable disease). The benefit of these 
responses mirrors that seen in KIT exon 11 mutations with 
a median PFS of approximately 2 years (34). Benefit from 
any second line palliative treatments, including sunitinib, 
seems to be limited with progression free survival averaging 
2 months (34). There are, however, cases of patients with 
exon 12 mutations who have achieved prolonged responses 
to sunitinib (35). There is insufficient data and experience 
with regorafenib in this population to help guide clinical 
decision making. 
Wild type GIST
GISTs without driver mutations in KIT or PDGFRA 
traditionally have been grouped together as wild-type GISTs. 
However, among the KIT/PDGFRA wild-type GISTs, 
there exist molecularly distinct sub-groups (36). Between 
20–40% have been found to be deficient for the succinate 
dehydrogenase (SDH) ubiquinone complex (SDHA, SDHB, 
SDHC, SDHD) (36). In addition, a fusion of ETV6-NTRK3 
has been identified in a subset of wild-type GIST which may 
have therapeutic implications (37). Finally, another 15% 
carry mutations in the RAS-RAF signaling pathway, most 
commonly BRAF. The remainder then fall into the KIT/
PDGFRα/RAS/SDH wild-type or ‘quadruple wild-type’ 
GISTs (38). Standard of care for wild-type GIST should be 
sarcoma center referral and clinical trial. 
As a group, wild-type GISTs have mixed response rates 
to first line TKIs, likely reflecting the heterogeneous nature 
of this category. Reported response rates to palliative 
imatinib are low (12,22). Further, in the adjuvant setting, 
it does not appear that imatinib offers any benefit for wild-
type GIST and is not routinely offered (21). Sunitinib, 
however, has shown activity with clinical benefit in 56% of 
wild-type patients and progression free survival averages 
of 19 months, mirroring the benefit seen in KIT exon 
9 patients (23). In the phase II regorafenib study, 8 wild-type 
GIST patients were included and had similar PFS to KIT 
exon 9 or 11 mutations (39).
Performing comprehensive genomic analysis of these 
tumors may be reasonable to search for molecular targets 
or opportunities for clinical trial enrollment. For example, 
there has been at least one report of a clinical response to 
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dabrafenib in a V600E BRAF mutant GIST (40).
Future therapies
As research into the understanding of GIST continues, 
three areas of current development are of interest: (I) 
pursuing new targets such as the transcription factor 
ETV1 through novel MEK inhibitors; (II) immunotherapy 
combinations with TKIs; and (III) the development of 
metabolic based therapies.
ETV1 is highly expressed in GISTs, regardless of 
mutational status. ETV1 seems to have a synergistic 
relationship with downstream KIT signaling through 
the MAP kinase pathway. Additionally, ETV1 has been 
demonstrated to be necessary for GIST cell survival (41). 
In mouse models, the combination of imatinib and a MEK 
inhibitor, MEK162, demonstrated near complete clinical 
responses. Phase Ib studies in imatinib refractory patients 
have been completed, and a phase II study in treatment 
naïve patients is ongoing (42).
A role for immune based therapy is in the early stages 
of investigation. The combination of ipilumumab with 
dasatinib was tested in 8 GIST patients who had progressed 
after at least 1 line of therapy. In this study, one patient had 
a durable response lasting over a year (59+ weeks). Plans for 
a phase II investigation are underway (42). The combination 
of ipilumumab and imatinib is also in the early phases of 
investigation (NCT01738139). 
Finally, metabolism is also an area of active investigation 
for the treatment of wild-type and cKIT/PDGFRα GIST. 
Given that succinate dehydrogenase deficiency is seen in 
many wild-type GISTs, and is thought to increase glutamine 
addiction, glutaminase inhibition using CB-839 is currently 
being studied in clinical trial NCT02071862. Finally, loss 
of expression of argininosuccinate synthetase 1 (ASS1) has 
been found in 97% of GIST (43). This metabolic deficiency, 
which is also common in other sarcomas, may allow for 
a new avenue of therapeutic opportunities as multi-agent 
therapies based on this deficiency using PEGylated arginine 
deiminase (ADI-PEG20) are currently being pursued.
Conclusions
The management of GISTs has evolved rapidly over the 
past two decades, driven by an ever-growing understanding 
of the disease’s molecular diversity. Today in the clinic, 
discussion of treatment options in both the adjuvant and 
metastatic settings is influenced by the information obtained 
by sequencing of the KIT and PDGFRα genes. As we look 
to the future, clinical trial development will become more 
molecularly focused, specifically looking for targets in each 




Conflicts of Interest: BVT has been an advisor to Novatris.
References
1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: 
pathology and prognosis at different sites. Semin Diagn 
Pathol 2006;23:70-83.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function 
mutations of c-kit in human gastrointestinal stromal 
tumors. Science 1998;279:577-80.
3. Edmonson JH, Marks RS, Buckner JC, et al. Contrast of 
response to dacarbazine, mitomycin, doxorubicin, and 
cisplatin (DMAP) plus GM-CSF between patients with 
advanced malignant gastrointestinal stromal tumors and 
patients with other advanced leiomyosarcomas. Cancer 
Invest 2002;20:605-12.
4. Oncology NCPGi. Soft Tissue Sarcoma. National 
Comprehensive Cancer Network; [May 28, 2016]; 
Available online: https://www.nccn.org/professionals/
physician_gls/pdf/sarcoma.pdf
5. Nilsson B, Bümming P, Meis-Kindblom JM, et al. 
Gastrointestinal stromal tumors: the incidence, prevalence, 
clinical course, and prognostication in the preimatinib 
mesylate era--a population-based study in western Sweden. 
Cancer 2005;103:821-9.
6. Uçar AD, Oymaci E, Carti EB, et al. Characteristics of 
Emergency Gastrointestinal Stromal Tumor (GIST). 
Hepatogastroenterology 2015;62:635-40.
7. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal 
of histogenesis. Am J Surg Pathol 1983;7:507-19.
8. Isozaki K, Hirota S, Nakama A, et al. Disturbed 
intestinal movement, bile reflux to the stomach, and 
deficiency of c-kit-expressing cells in Ws/Ws mutant rats. 
Gastroenterology 1995;109:456-64.
9. West RB, Corless CL, Chen X, et al. The novel marker, 
DOG1, is expressed ubiquitously in gastrointestinal 
stromal tumors irrespective of KIT or PDGFRA mutation 
472 Oppelt et al. Mutational therapy and GIST
© Journal of Gastrointestinal Oncology. All rights reserved. J Gastrointest Oncol 2017;8(3):466-473jgo.amegroups.com
status. Am J Pathol 2004;165:107-13.
10. Barnett CM, Corless CL, Heinrich MC. Gastrointestinal 
stromal tumors: molecular markers and genetic subtypes. 
Hematol Oncol Clin North Am 2013;27:871-88. 
11. Heinrich MC, Owzar K, Corless CL, et al. Correlation 
of kinase genotype and clinical outcome in the North 
American Intergroup Phase III Trial of imatinib mesylate 
for treatment of advanced gastrointestinal stromal 
tumor: CALGB 150105 Study by Cancer and Leukemia 
Group B and Southwest Oncology Group. J Clin Oncol 
2008;26:5360-7. 
12. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT 
mutations and dose selection for imatinib in patients with 
advanced gastrointestinal stromal tumours. Eur J Cancer 
2006;42:1093-103.
13. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant 
imatinib mesylate after resection of localised, primary 
gastrointestinal stromal tumour: a randomised, double-
blind, placebo-controlled trial. Lancet 2009;373:1097-104.
14. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three 
years of adjuvant imatinib for operable gastrointestinal 
stromal tumor: a randomized trial. JAMA 2012;307:1265-72. 
15. Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant 
Imatinib for High-Risk GI Stromal Tumor: Analysis of a 
Randomized Trial. J Clin Oncol 2016;34:244-50.
16. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy 
and safety of imatinib mesylate in advanced gastrointestinal 
stromal tumors. N Engl J Med 2002;347:472-80.
17. Verweij J, Casali PG, Zalcberg J, et al. Progression-free 
survival in gastrointestinal stromal tumours with high-dose 
imatinib: randomised trial. Lancet 2004;364:1127-34. 
18. Blanke CD, Rankin C, Demetri GD, et al. Phase III 
randomized, intergroup trial assessing imatinib mesylate at 
two dose levels in patients with unresectable or metastatic 
gastrointestinal stromal tumors expressing the kit receptor 
tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32.
19. Demetri GD, van Oosterom AT, Garrett CR, et al. 
Efficacy and safety of sunitinib in patients with advanced 
gastrointestinal stromal tumour after failure of imatinib: a 
randomised controlled trial. Lancet 2006;368:1329-38.
20. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and 
safety of regorafenib for advanced gastrointestinal stromal 
tumours after failure of imatinib and sunitinib (GRID): 
an international, multicentre, randomised, placebo-
controlled, phase 3 trial. Lancet 2013;381:295-302.
21. Corless CL, Ballman KV, Antonescu CR, et al. Pathologic 
and molecular features correlate with long-term 
outcome after adjuvant therapy of resected primary GI 
stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 
2014;32:1563-70.  
22. Heinrich MC, Corless CL, Demetri GD, et al. Kinase 
mutations and imatinib response in patients with 
metastatic gastrointestinal stromal tumor. J Clin Oncol 
2003;21:4342-9.
23. Heinrich MC, Maki RG, Corless CL, et al. Primary and 
secondary kinase genotypes correlate with the biological 
and clinical activity of sunitinib in imatinib-resistant 
gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-9. 
24. Heinrich MC, Corless CL, Blanke CD, et al. Molecular 
correlates of imatinib resistance in gastrointestinal stromal 
tumors. J Clin Oncol 2006;24:4764-74.
25. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase 
inhibitor SU11248 against gastrointestinal stromal tumor 
mutants refractory to imatinib mesylate. Clin Cancer Res 
2006;12:2622-7.
26. Patrikidou A, Domont J, Chabaud S, et al. Long-term 
outcome of molecular subgroups of GIST patients treated 
with standard-dose imatinib in the BFR14 trial of the 
French Sarcoma Group. Eur J Cancer 2016;52:173-80.
27. Lasota J, Corless CL, Heinrich MC, et al. 
Clinicopathologic profile of gastrointestinal stromal 
tumors (GISTs) with primary KIT exon 13 or exon 17 
mutations: a multicenter study on 54 cases. Mod Pathol 
2008;21:476-84.
28. Garner AP, Gozgit JM, Anjum R, et al. Ponatinib inhibits 
polyclonal drug-resistant KIT oncoproteins and shows 
therapeutic potential in heavily pretreated gastrointestinal 
stromal tumor (GIST) patients. Clin Cancer Res 
2014;20:5745-55.
29. Evans EK, Hodous BL, Gardino AK, et al. Abstract 
791: BLU-285, the first selective inhibitor of PDGFRα 
D842V and KIT Exon 17 mutants. Cancer Research 
2015;75:Abstr 791.
30. Corless CL, Schroeder A, Griffith D, et al. PDGFRA 
mutations in gastrointestinal stromal tumors: frequency, 
spectrum and in vitro sensitivity to imatinib. J Clin Oncol 
2005;23:5357-64.
31. Sadovnik I, Lierman E, Peter B, et al. Identification of 
Ponatinib as a potent inhibitor of growth, migration, and 
activation of neoplastic eosinophils carrying FIP1L1-
PDGFRA. Exp Hematol 2014;42:282-293.e4.
32. Heinrich MC, Griffith D, McKinley A, et al. Crenolanib 
inhibits the drug-resistant PDGFRA D842V mutation 
associated with imatinib-resistant gastrointestinal stromal 
tumors. Clin Cancer Res 2012;18:4375-84. 
33. Yoo C, Ryu MH, Jo J, et al. Efficacy of Imatinib in Patients 
473Journal of Gastrointestinal Oncology Vol 8, No 3 June 2017
© Journal of Gastrointestinal Oncology. All rights reserved. J Gastrointest Oncol 2017;8(3):466-473jgo.amegroups.com
with Platelet-Derived Growth Factor Receptor Alpha-
Mutated Gastrointestinal Stromal Tumors. Cancer Res 
Treat 2016;48:546-52.
34. Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of 
patients with platelet-derived growth factor receptor alpha-
mutated gastrointestinal stromal tumors in the tyrosine 
kinase inhibitor era. Clin Cancer Res 2012;18:4458-64. 
35. Brohl AS, Demicco EG, Mourtzikos K, et al. Response to 
sunitinib of a gastrointestinal stromal tumor with a rare 
exon 12 PDGFRA mutation. Clin Sarcoma Res 2015;5:21. 
36. Boikos SA, Pappo AS, Killian JK, et al. Molecular Subtypes 
of KIT/PDGFRA Wild-Type Gastrointestinal Stromal 
Tumors: A Report From the National Institutes of Health 
Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 
2016;2:922-8.
37. Brenca M, Rossi S, Polano M, et al. Transcriptome 
sequencing identifies ETV6-NTRK3 as a gene fusion 
involved in GIST. J Pathol 2016;238:543-9. 
38. Pantaleo MA, Nannini M, Corless CL, et al. Quadruple 
wild-type (WT) GIST: defining the subset of GIST that 
lacks abnormalities of KIT, PDGFRA, SDH, or RAS 
signaling pathways. Cancer Med 2015;4:101-3.
39. George S1, Wang Q, Heinrich MC, et al. Efficacy and 
safety of regorafenib in patients with metastatic and/or 
unresectable GI stromal tumor after failure of imatinib 
and sunitinib: a multicenter phase II trial. J Clin Oncol 
2012;30:2401-7. 
40. Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant 
gastrointestinal stromal tumor: first report of regression 
with BRAF inhibitor dabrafenib (GSK2118436) and whole 
exomic sequencing for analysis of acquired resistance. 
Oncotarget 2013;4:310-5.
41. Ran L, Sirota I, Cao Z, et al. Combined inhibition of 
MAP kinase and KIT signaling synergistically destabilizes 
ETV1 and suppresses GIST tumor growth. Cancer Discov 
2015;5:304-15. 
42. Shoushtari AN, D'Angelo SP, Keohan ML, et al. 
Combined KIT and CTLA-4 blockade in patients with 
refractory GIST and other advanced sarcomas. J Clin 
Oncol 2014;32:Abstr 10521.
43. Bean GR, Kremer JC, Prudner BC, et al. A metabolic 
synthetic lethal strategy with arginine deprivation and 
chloroquine leads to cell death in ASS1-deficient sarcomas. 
Cell Death Dis 2016;7:e2406. 
Cite this article as: Oppelt PJ, Hirbe AC, Van Tine BA. 
Gastrointestinal stromal tumors (GISTs): point mutations 
matter in management, a review. J Gastrointest Oncol 
2017;8(3):466-473. doi: 10.21037/jgo.2016.09.15
